IBBL (Integrated Biobank of Luxembourg) works in close collaboration with national players to support Luxembourgish biomedical research across a variety of areas. An instance of successful cooperation is the SOCS (Suppressor Of Cytokine Signaling) project, which saw the discovery of the protein MYO5B as a colorectal cancer biomarker in 2017.
IBBL has been supporting Luxembourg’s colorectal cancer research through the SOCS (Suppressor Of Cytokine Signalling) project – a partnership between IBBL, the Life Sciences Research Unit of the University of Luxembourg, the Luxembourg Institute of Health (LIH), the Luxembourg Centre for Systems Biomedicine (LCSB) and the National Health Laboratory (LNS). Under the project, IBBL set up an independent cohort of colorectal cancer patients in close cooperation with the other partners, which supported the identification of MYO5B as a novel prognostic biomarker.
Watch the video below to find out more about how the winning partnership underscoring the SOCS project is contributing to improving health outcomes for Luxembourg’s colon cancer patients!